secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2022-03-28T23:59:59+00:00
Accession:  0001559053-22-000014
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears IND for Prothena's PRX012 subcutaneous anti-Aβ antibody; Phase 1 SAD study initiated
--------------------------------------------------------------------------------

- FDA cleared IND for PRX012, a potential best-in-class anti-amyloid beta antibody for Alzheimer's disease.
- Phase 1 single ascending dose study in healthy volunteers and AD patients has started; MAD study expected by year-end 2022.
- PRX012 designed for subcutaneous dosing with high binding potency; preclinical data show plaque occupancy at low doses.
- Prothena expects PRX012 to serve as a foundational anti-Aβ treatment with convenient administration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905322000014/0001559053-22-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905322000014/prta-20220328.htm
  HTML page:      https://secwatch.observer/filing/0001559053-22-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer